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ABSTRACT
Background: Regular use of inhaled b2-agonists has
been associated with a paradoxical loss of asthma control
and a deterioration of airway hyper-responsiveness, but
the underlying mechanism is unknown. The neurotrophin
brain-derived neurotrophic factor (BDNF) has recently
been identified as a mediator of airway hyper-respon-
siveness in asthma.
Methods: Eighteen patients with mild allergic asthma
who did not use any regular antiasthmatic therapy inhaled
the long-acting b2-agonist salmeterol for 2 weeks
followed by 2 weeks of combination therapy with
salmeterol and the corticosteroid fluticasone. Airway
responsiveness to histamine and BDNF concentrations in
blood were assessed prior to entry, after 14 days of
salmeterol therapy and after 14 days of combination
therapy. In a separate experiment, salmeterol effects on
BDNF release by human peripheral blood mononuclear
cells were assessed.
Results: Monotherapy with salmeterol significantly
increased BDNF concentrations in serum and platelets.
This increase was abolished by the addition of fluticasone
to the treatment. The findings were confirmed in vitro:
salmeterol increased the release of BDNF by mononuclear
cells, and this was inhibited by co-incubation with
fluticasone. Increased BDNF concentrations in serum and
platelets correlated with the deterioration of airway hyper-
responsiveness following salmeterol monotherapy. In
contrast, there was no association between b2-receptor
polymorphisms and changes in airway responsiveness.
Conclusion: Increased BDNF concentrations may underly
the adverse effects of salmeterol monotherapy on airway
responsiveness in asthma.
Trial registration number: NCT00736801.
Asthma is characterised by airway inflammation,
airway hyper-responsiveness (AHR) and a reversible
airflow limitation.
1 Inhaled corticosteroids (ICSs)
are the treatment of choice for asthma. In more
severe asthma, international guidelines recommend
that ICSs can be combined with inhaled long-acting
b2-agonists (LABAs) such as salmeterol.
2 Mono-
therapy with b2-agonists has not been recom-
mended due to accumulating evidence suggesting a
loss of control and an excess mortality in asthma
with this treatment.
3 Several studies reported that
unbalanced use of short-acting sympathomimetic
bronchodilators as well as LABAs can cause a
deterioration in asthma control, and increase
exacerbations and hospital admissions, most prob-
ably as a class effect of b2-agonists.
4–8
Well-controlled clinical studies have demon-
strated that regular inhalation of short acting b2-
agonists such as fenoterol, albuterol and terbutaline
increases airway responsiveness to histamine or
methacholine.
491 0This effect is not attributable to
a b2-receptor subsensitisation.
11 12 In addition, the
regular use of albuterol has been shown to increase
the allergen-induced early
13 and late asthmatic
response.
14 Carefully conducted studies on the
effect of regular use of LABAs in patients with
asthma have only been performed in children
where regular monotherapy with salmeterol also
led to an increase in AHR.
15 16 Futhermore, regular
inhalation of short- (terbutaline) as well as long-
acting b2-agonists (salmeterol) led to a tolerance of
the bronchoprotective actions of both drugs
against non-specific bronchoconstrictor stimuli.
17 18
In two more recent large-scale trials, salmeterol
treatment was even associated with excess mor-
tality in asthma.
19 20 A trend towards excess
mortality in asthma has recently also been
reported for formoterol.
21 However, the mechan-
ism by which the regular inhalation of b2-agonists
contributes to increased airway responsiveness and
a loss in asthma control is unclear.
The neurotrophin brain-derived neurotrophic
factor (BDNF), a crucial regulator of neuronal
activity in adults,
22 has been linked to several
features of asthma. BDNF is upregulated in allergic
airway inflammation and induces AHR and airway
obstruction in an animal model of allergic asthma,
via an increase of neuronal sensitivity and activity
in the airways.
23–26 In patients with asthma,
systemic concentrations of BDNF are increased
and these concentrations correlate with AHR.
27
Following local allergen challenge, endobronchial
BDNF levels increase significantly in patients with
asthma.
28 In addition, there is evidence in human
asthma that corticosteroids prevent allergen-
induced increases in AHR
29 and reduce BDNF
concentrations.
27 30 31 However, there is no infor-
mation on the effects of b2-agonists on BDNF
concentrations in asthma. In this report, we
investigate the effect of monotherapy with a
LABA on BDNF concentrations and airway respon-
siveness in patients with asthma.
METHODS
Study design
The study was performed between September and
December 2006 in Rostock (Germany). Patients
were recruited by newspaper advertisements.
Patients were eligible when they met the following
criteria: age .18 years, a doctor’s diagnosis of
allergic asthma, a documented sensitisation to
aero-allergens (pollen, animal hair or house dust
mite), no regular treatment (only short-acting
inhalers on demand were allowed), no history of
or evidence for chronic disease other than asthma
and no history of smoking. Prior to inclusion,
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Pneumology (University of Rostock, Germany). Recruited
patients were included in the study if they met the following
criteria: a prebronchodilator forced expiratory volume in 1 s
(FEV1) .80% of the predicted value, a provocative concentra-
tion of histamine causing a 20% fall in FEV1 (PC20)o f,8m g
histamine/ml and the absence of any signs or symptoms of an
infection. After inclusion in the study, blood was collected and
patients were instructed in the use of the inhalation device.
Patients were asked to inhale salmeterol xinafoate 50 mg
(Serevent Discus, GlaxoSmithKline (GSK), Brentford,
Middlesex, UK) twice in the morning and twice in the evening
for 2 weeks. In the following 2 weeks, patients were asked to
inhale salmeterol xinafoate 50 mg and fluticasone propionate
250 mg (Viani Discus, GSK) twice in the morning and twice in the
evening (fig 1). For safety reasons, patients were asked to record
their peak flow daily, and to inform the monitor in case of any
adverse event or symptomatic deterioration or a drop in peak
expiratory flow (PEF) below 3 l/s. After 14 days of salmeterol
therapy and after 14 days of combination therapy, body
plethysmography, assessment of airway responsiveness and blood
sampling were repeated (fig 1). The study medication was
withheld for >12 h prior to lung function testing. The study
was approved by the ethics committee of the A ¨rztekammer
Mecklenburg-Vorpommern (Rostock, Germany). Participating
subjects gave their written informed consent.
Clinical and laboratory procedures
Pulmonary function, airway responsiveness to histamine, blood
cell counts and BDNF concentrations were assessed as
previously described.
27 32 Monocyte-enriched human peripheral
blood mononuclear cells were isolated and cultured as
described
27 and stimulated with tumour necrosis factor a
(TNFa, 50 ng/ml), in the presence or absence of salmeterol
xinafoate and/or fluticasone propionate (GSK), for 24 h. Because
fluticasonepropionatewas dissolved inalcohol,resulting in0.01%
alcohol in the culture, 0.01% alcohol was added to control and
salmeterol xinafoate cultures. BDNF concentrations measured in
supernatants were corrected for the percentage of non-viable cells
to exclude artefacts due to corticosteroid-induced apoptosis, as
described.
27 Polymorphisms of the b2-receptor were analysed in
blood containing ethylenediaminetetraacetic acid (EDTA) using
PCR by a commercial laboratory (IMGM Laboratories,
Martinsried, Germany).
Statistical analysis
Data were analysed using SPSS (Chicago, Illinois, USA). Most
parameters were non-normally distributed. Correlation analyses
between the changes in BDNF concentrations and PC20 after
14 days of salmeterol therapy and after 14 days of combination
therapy, and correlation analyses between b2-receptor poly-
morphisms and the changes of the PC20 after 14 days of
salmeterol therapy were performed using the Spearman’s
correlation coefficient. Lung function parameters, platelet
counts and BDNF concentrations prior to entry, after 14 days
of salmeterol therapy and after 14 days of combination therapy
were compared using the signed ranks Wilcoxon test for related
samples. Means of BDNF concentrations in cell culture super-
natants after 24 h of incubation with TNFa alone and TNFa
plus salmeterol xinafoate, fluticasone propionate or salmeterol
xinafoate/fluticasone propionate were compared using analysis
of variance (ANOVA; with SPSS). Probability values of p ,0.05
were regarded as statistically significant.
RESULTS
Patient characteristics
Thirty-five patients were recruited (fig 1). Of these, 14 patients
did not meet the inclusion criteria (n=11 had a PC20 of .8 mg/
Figure 1 Study design. Body
plethysmography, assessment of airway
responsiveness to histamine and blood
collection for brain-derived neurotrophic
factor (BDNF) measurements were
performed prior to entry (white box), after
14 days of salmeterol therapy (light grey
box) and after 14 days of combination
therapy (dark grey box). FEV1, forced
expiratory volume in 1 s as a percentage
of the predicted value (% pred.);
PC20, provocative concentration of
histamine causing a 20% fall in FEV1.
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predicted value). Of the remaining 21 patients who were
included in the study, 3 patients did not complete the study
(one patient withdrew consent during salmeterol therapy due to
an unacceptable subjective increase in asthma symptoms; two
patients erroneously inhaled the study medication in the
morning prior to lung function testing, and were excluded
from the study). The baseline characteristics of the 18 patients
which completed the study protocol (fig 1) are given in table 1.
Three patients (16%) reported mild adverse effects (subjective
discomfort or worsened dyspnoea) during salmeterol mono-
therapy, whereas none of the patients reported adverse effects
during combination therapy. There were no severe adverse
effects (leading to hospitalisation or death) during the study.
Lung function and AHR
The FEV1 (% predicted) and PEF (% predicted) did not change
significantlyfollowing14 daysofsalmeterolmonotherapy(fig2).
Treatment with salmeterol and fluticasone led to a numerical
increase in median FEV1 and PEF values, as compared with the
baseline and with salmeterol monotherapy. However, the
differences were not statistically significant (fig 2). Although
there was no statistically significant change in AHR when the
whole patient population was analysed, 12 of the 18 patients
(67%) demonstrated an increase in AHR as measured by lower
PC20 values to histamine following salmeterol monotherapy
compared with baseline (fig 3). In contrast, when treated with a
combination of salmeterol and fluticasone, nearly all patients
displayed an increase in PC20 values (fig 3). AHR improved with
combination therapy when compared with baseline in 15
patients (83%), and when compared with values obtained after
salmeterol monotherapy in 16 patients (89%). This resulted in a
statistically significant increase in the overall PC20 following the
addition of fluticasone to salmeterol therapy (fig 3).
BDNF concentrations in serum, platelets and plasma
There was no statistically significant difference in BDNF
concentrations in plasma at baseline (median: 0.09 ng/ml),
after salmeterol monotherapy (median: 0.08 ng/ml) and after
combination therapy (median: 0.08 ng/ml). In contrast, there
was a statistically significant increase in BDNF concentrations
in serum and platelets after salmeterol monotherapy compared
with baseline. Both serum and platelet BDNF concentrations
decreased significantly after 14 days of combination therapy
(fig 4). There were no statistically significant changes in platelet
counts at baseline (median: 232610
9/l), after salmeterol mono-
therapy (median: 247610
9/l) and after combination therapy
(median: 255610
9/l).
Association of BDNF with changes in PC20
Changes in BDNF concentrations in serum and platelets were
correlated with the changes in PC20 values following salmeterol
monotherapy (fig 5). Although BDNF levels decreased and PC20
valuesincreasedsignificantlyfollowingcombinationtherapywith
salmeteroland fluticasone, changesinBDNFlevelswerenolonger
correlated with the changes in PC20 following combination
therapy (p.0.05 for serum and platelet BDNF concentrations).
Effect of salmeterol on BDNF secretion by mononuclear cells
To substantiate the in vivo effects of salmeterol and combination
therapy on BDNF concentrations, monocyte-enriched peripheral
bloodmononuclearcellswereisolatedfrom22healthyvolunteers,
and stimulated with TNFa for 24 h. Fluticasone significantly
suppressed BDNF secretion, whereas salmeterol significantly
increased BDNF secretion, as compared with medium control
(fig 6). BDNF secretion after co-incubation with salmeterol and
fluticasone was not significantly different from medium control
(p=0.62), and significantly lower than BDNF secretion after
incubation with salmeterol alone (fig 5).
Table 1 Baseline patient characteristics
Patient no Age Sex
Years since
diagnosis
PC20
(mg/ml)
FEV1
(% pred) Allergies
b2-Receptor polymorphisms
arg16gly gln27glu
1 20 M 13 4.0 91.9 P, D, A Gly/Gly Gln/Gln
2 19 M 5 3.8 81.8 D, A Gly/Gly Glu/Glu
3 20 M 8 4.5 105.7 P, D Arg/Gly Gln/Gln
4 18 M 5 0.2 84.2 P Arg/Gly Gln/Glu
5 36 F 5 5.0 103.6 P, D, A Gly/Gly Gln/Glu
6 19 F 11 3.3 102.2 P, D, A Gly/Gly Gln/Gln
7 39 F 6 4.2 86.8 P, A Arg/Arg Gln/Gln
8 20 F 10 3.8 109.1 P, D Arg/Gly Gln/Glu
9 42 F 10 5.5 115.3 P Arg/Gly Gln/Glu
10 44 M 8 0.4 82.5 D Arg/Gly Gln/Glu
11 18 M 3 2.8 95.8 P Gly/Gly Glu/Glu
12 29 M 3 5.5 88.7 P, A Gly/Gly Glu/Glu
13 18 M 6 0.8 89.9 D, A Arg/Gly Gln/Gln
14 38 M 28 0.8 92.0 P, D Arg/Gly Gln/Glu
15 26 F 10 1.5 93.2 P, D Arg/Gly Gln/Glu
16 19 M 10 1.4 97.3 P, D, A Gly/Gly Glu/Glu
17 19 F 8 8.0 87.0 P, D, A Arg/Gly Gln/Glu
18 20 F 15 2.7 106.0 P Arg/Gly Gln/Glu
Median 20 8 3.6 92.6
A, animal hair; Arg, arginine; D, house dust mite; F, female; FEV1, forced expiratory volume in 1 s as a percentage of the predicted
value (% pred); Gln, glutamine; Glu, glutamic acid; Gly, glycine; M, male; P, pollen; PC20, provocative concentration of histamine
causing a 20% fall in FEV1.
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In order to test if the effects of salmeterol on airway
responsiveness were related to b2-receptor polymorphisms, the
b2-receptor polymorphisms arg16gly (glycine for arginine in
position 16) and gln27glu (glutamic acid for glutamine in
position 27) were analysed (table 1). As far as the arg16gly
polymorphism is concerned, 7 patients (39%) were glycine
homozygotes, 1 patient (6%) was an arginine homozygote and
10 patients (55%) were heterozygotes. As far as the gln27glu
polymorphism is concerned, 4 patients (22%) were glutamic
acid homozygotes, 5 patients (28%) were glutamine homo-
zygotes and 9 patients (50%) were heterozygotes (table 1).
There was no statistically significant association between the
changes in PC20 after salmeterol treatment and the b2-receptor
polymorphism arg16gly (r=0.11, p=0.65) or the b2-receptor
polymorphism gln27glu (r=0.34, p=0.17).
DISCUSSION
Inhaled b2-agonists provide rapid bronchodilation and have
been shown to improve asthma control in a fixed combination
with ICSs.
33 34 However, there is now increasing evidence for a
paradoxical loss of asthma control and an increase in asthma
mortality following b2-agonist monotherapy.
31 92 0An explana-
tion for this observation is lacking. Several reports highlight that
regular treatment with b2-agonists in patients with asthma can
increase airway responsiveness
491 0due to mechanisms which
are incompletely understood.
35 There is, however, evidence that
increases in airway responsiveness following b2-agonist treat-
ment are at least in part explained by changes in the reactivity
of airway nerves.
36
Mediators with the potential to change neuronal reactivity in
the airways are neurotrophins such as BDNF which induce long-
term changes in neuronal function and activity.
22 37 Animal
studies have shown that the production of BDNF by leucocytes
and epithelia is strongly upregulated in allergic airway
inflammation.
23 26 In a functional study, the inhibition of
endogenous BDNF reduced AHR in allergen-challenged mice,
whereas administration of recombinant BDNF was sufficient to
induce AHR in healthy mice.
25 In the same study, it was
demonstrated that these effects of BDNF are due to changes in
the neuronal reactivity within the airways.
25 These findings
have recently been confirmed in a study with guinea pigs.
38
Thus, there is now accumulating evidence from animal models
that BDNF enhances neuronal reactivity in the airways and
contributes to neuronal dysfunction and AHR in allergic airway
inflammation.
24
In patients with asthma, enhanced local BDNF concentra-
tions in the lung
28 are mirrored by enhanced BDNF concentra-
tions in circulating platelets.
27 BDNF is produced neither by
platelets nor by its precursors, but actively acquired by
platelets.
39 Therefore, platelet BDNF appears to be an estimate
for the average BDNF secretion in organs of the human body
Figure 2 Lung function. Shown are
forced expiratory volume in 1 s (FEV1;%
predicted) values (A) and peak expiratory
flow (PEF; % predicted) values (B) prior to
entry (white box), after 14 days of
salmeterol therapy (light grey box) and
after 14 days of combination therapy
(dark grey box) of n=18 patients with
allergic asthma. Boxplot graphs display
the median (line within the box),
interquartile range (edges of the box) and
the range of all values less distant than
1.5 interquartile ranges from the upper or
lower quartile (vertical lines).
S, salmeterol; F, fluticasone.
Figure 3 Airway responsiveness to histamine. PC20 (provocative
concentration of histamine causing a 20% fall in the forced expiratory
volume in 1 s) values are shown for each patient (n=18 patients) prior
to entry (Baseline), after 14 days of salmeterol therapy and after 14 days
of combination therapy. Patients with a decrease in PC20 values after
14 days of salmeterol therapy are displayed with continuous lines.
Patients with an increase in PC20 values after 14 days of salmeterol
therapy are displayed with dashed lines. S, salmeterol; F, fluticasone.
Asthma
766 Thorax 2009;64:763–769. doi:10.1136/thx.2008.110916over a period of several days.
32 Accordingly, platelet BDNF (but
not plasma BDNF) has been shown to correlate with the
severity of AHR.
27 This association may simply reflect the fact
that enhanced BDNF concentrations in the airways lead to both
AHR and an enhanced uptake of BDNF into circulating
platelets. However, it is also conceivable that platelet BDNF
plays a genuine role in asthma. Platelets have been shown to
migrate actively into the lung and to contribute to functional
changes within the airways in allergic airway inflammation.
40 41
Thus, it can be speculated that not only a BDNF overproduction
in the airways by leucocytes and epithelia, but also an enhanced
deposition of BDNF by platelets might contribute to the
development of AHR in asthma.
In the present study, 14 days of treatment with salmeterol in
patients with asthma led to a significant increase in platelet
BDNF concentrations and this was correlated with changes in
airway responsiveness. In addition, these effects were abolished
by adding inhaled fluticasone to the treatment. Thus, the
correlation between the changes in AHR and the changes in
BDNF concentrations suggests that BDNF might indeed
contribute to the development of AHR in asthma and to some
of the adverse effects of a salmeterol monotherapy. The
mechanisms underlying the induction of BDNF by salmeterol
are as yet unclear. However, salmeterol has been shown to
increase the transcription of genes with cAMP response
elements in their promoters.
42 Thus, as BDNF is known to have
active cAMP response elements in its promoter,
43 salmeterol
could enhance BDNF transcription via this pathway.
Concomitant treatment with fluticasone led to a significant
decrease in platelet BDNF levels in vivo and to a significant
reduction in BDNF secretion by leucocytes in vitro. It has
already been shown that ICSs such as fluticasone reduce BDNF
secretion by leucocytes
27 as well as BDNF serum levels in
patients with allergic asthma.
31 This is not specific for
fluticasone because other corticosteroids (such as prednisolone
and dexamethasone) also suppress BDNF secretion.
27 30 ICSs can
prevent the increase in AHR following allergen challenge,
29
which is associated with an increase in BDNF concentrations.
28
Accordingly, the inhibition of BDNF production by ICSs as
observed in this and previous studies
27 further suggests that
BDNF might indeed participate in the pathogenesis of AHR.
Therefore, some of the beneficial effects of ICS in a combination
with LABA in asthma might be related to a suppression of
LABA-induced BDNF overexpression. It is of note that the
Figure 4 Brain-derived neurotrophic
factor (BDNF) concentrations in serum
and platelets. Shown are BDNF
concentrations in serum (ng BDNF/ml
serum) and platelets (pg BDNF/10
6
platelets) prior to entry (white box), after
14 days of salmeterol monotherapy (light
grey box) and after 14 days of
combination therapy (dark grey box) of
n=18 patients with allergic asthma.
Boxplot graphs display the median (line
within the box), interquartile range (edges
of the box) and the range of all values less
distant than 1.5 interquartile ranges from
the upper or lower quartile (vertical lines).
S, salmeterol; F, fluticasone.
Figure 5 Association of brain-derived
neurotrophic factor (BDNF) with changes
in PC20 (provocative concentration of
histamine causing a 20% fall in the forced
expiratory volume in 1 s). Shown are
correlations between changes in BDNF
concentrations in serum (A) or platelets
(B) and changes in the PC20 values
(histamine) after 14 days of salmeterol
therapy, as compared with the baseline
before therapy. Each dot represents one
patient; the line is the regression line
calculated with SPSS (Chicago, Illinois,
USA). Spearman’s rank correlation
coefficient (r) and the significance of the
correlation (p) are given above each
graph.
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PC20 values following combination therapy. This might be due
to the fact that fluticasone not only suppresses BDNF, but has
several other effects on a variety of cell types which influence
airway responsiveness.
In this study, a deterioration in AHR following salmeterol
monotherapy was observed in the majority (67%) of the
patients. These data are consistent with studies showing
adverse effects of long-acting
15 16 and short-acting b2-ago-
nists
491 0on airway responsiveness in asthma. Genotyping for
two b2-receptor polymorphisms implicated in the response to
b2-agonists
44 or persistence of asthma
45 showed that the changes
in PC20 values following salmeterol monotherapy were not
related to these polymorphisms. Thus, although our study is
clearly underpowered to exclude other detrimental effects of b2-
receptor polymorphisms on asthma control, the observed effects
on PC20 values do not appear to be related to these polymorph-
isms. This is in line with a recent analysis suggesting that b2-
receptor polymorphisms do not affect the therapeutic response
to LABA in patients with asthma.
46 Our observation that the
majority of patients with mild asthma developed an increase in
AHR following salmeterol monotherapy suggests a susceptible
subpopulation of patients which cannot be identified by b2-
receptor polymorphisms or other clinical characteristics
obtained in our study.
One limitation of this study is the lack of a crossover design.
However, this was omitted due to ethical and safety concerns. A
study arm in which patients would have left the study after
regular monotherapy with a b2-agonist (with possibly detri-
mental effects on asthma control and mortality) was considered
ethically inappropriate based on the strong recommendations in
international guidelines that LABAs should not be used as
monotherapy in asthma.
2 Thus, although this may appear
overcautious in patients with mild asthma, a crossover design
was rejected. This decision has been confirmed in part by our
results which showed a deterioration of AHR and mild adverse
effects in a substantial portion of the participants following
salmeterol monotherapy. Another potential pitfall in the design
of our study is the lack of a placebo arm. However, although
this might have at least theoretically improved the study, it was
prospectively decided that this approach would not offer
advantages because the high dose of the b2-agonist (100 mgo f
salmeterol twice daily) unblinds such a design due to its
inherent side effects. Furthermore, in our patient population,
baseline parameters are representative of a placebo arm since
baseline treatment (short-acting bronchodilators on an as-
needed basis) was maintained unchanged throughout the study.
In conclusion, we show that unbalanced monotherapy with
salmeterol in patients with mild asthma increases BDNF
production and storage and that changes in AHR are associated
with this effect. We, therefore, hypothesise that augmented
BDNF concentrations explain some of the adverse effects of b2-
agonists in asthma. Further studies in patients with more
severe airflow obstruction are warranted to confirm these
findings.
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